| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8778391 | European Urology | 2018 | 7 Pages |
Abstract
In this randomised trial, we tested whether chemotherapy after surgery for high-risk prostate cancer decreases the risk of a rising prostate-specific antigen. We found no benefit from docetaxel given after radical prostatectomy.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Göran M. Ahlgren, Per Flodgren, Teuvo L.J. Tammela, Pirkko Kellokumpu-Lehtinen, Michael Borre, Anders Angelsen, Jon Reidar Iversen, Asgerdur Sverrisdottir, Eirikur Jonsson, Lisa Sengelov,